JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $20
JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers the price target from $23 to $20.
Read original at benzingaStocks · News reference
Oculis Doses First PIONEER-1 Patient As Privosegtor Advances Into Registrational Testing For Optic Neuritis With FDA SPA Agreement
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 24, 2026, 8:15 AM
- Checked
- Aug 24, 2026, 1:28 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Oculis Acquires Accure's Privosegtor And ACT-02 Assets In Deal Worth $3.8M Upfront Cash And Up To 2,050,000 Shares
Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creationTransaction consideration includes $3.8 million up-front cash payment at closing and up to
Read original at benzingaOculis Holding Q2 EPS $(0.20) Beats $(0.48) Estimate, Sales $392.150K Beat $260.000K Estimate
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.48) by 58.33 percent. This is a 64.91 percent increase over losses of $(0.57) per share from
Read original at benzinga